Medical

Researchers from the University of Goteborg, Sweden, have found that an intranasal cellulose powder significantly reduced allergic rhinitis symptoms in children. The double-blind study involved 53 children with allergies to birch pollen. Nils Åberg, associate… Read more . . .

A study of COPD patients by researchers from Johhs Hopkins found that use of inhaled corticosteroids for six months increased the risk of bone fracture by 27%. The researchers reviewed data from both double-blind and… Read more . . .

An intranasal formulation of diazepam being developed by Neurelis for the treatment of acute seizures outside of a hospital setting demonstrated 96% bioavailability compared to the only currently approved treatment, a rectal diazepam gel. The… Read more . . .

A Phase 2b study of Aradigm’s inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchietasis has shown a significant reduction in Pseudomonas aeruginosa colony forming units per gram of sputum (CFUs) over a 28-day treatment… Read more . . .

An article by Johns Hopkins researchers published in the BMJ, the British Medical Journal, suggests that patients using the Respimat tiotropium soft mist inhaler for the treatment of COPD are 52% more likely to die… Read more . . .

At the European Cystic Fibrosis Conference in Hamburg, Germany, Insmed presented data showing that Arikace liposomal amikacin for inhalation improved lung function in CF patients over six cycles of treatment. Each cycle included 28 days… Read more . . .

A Phase 1 clinical trial of an inhaled dry powder formulation of atropine for the treatment of nerve agent poisoning has been completed successfully, according to MicroDose Therapeutx. MicroDose subsidiary MicroDose Defense Products is developing… Read more . . .

GSK and Theravance have announced results for two Phase 3 studies of its ICS/LABA combo DPI Relovair for the treatment of COPD. The product combines fluticasone furoate and vilanterol. The companies said that the studies… Read more . . .